Agios Pharmaceuticals Inc - AGIO Quarterly EPS earnings growth

Agios Corp - graphic logo of issuer AGIO

The business resilience of Agios Pharmaceuticals (AGIO) relies on its own scientific foundation in the US. The current quarterly EPS growth rate demonstrates price stability, with 39.40 representing the current metric value. The financial cushion is bolstered by its leadership status in the therapy of genetic pathologies and high margins resulting from a narrow specialization in rare metabolic disorders.

Agios Pharmaceuticals, Inc. (AGIO) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for Agios Pharmaceuticals (AGIO)

- share price and consensus valuation forecast:
Analysis of all company metrics:Agios Pharmaceuticals
Manufactured product of Agios Corp

Investors seek a fundamental balance between asset quality and the market valuation of the business. Quarterly earnings per share (EPS) growth captures net income dynamics, allowing for the determination of a fair value equilibrium point. For Agios Pharmaceuticals (AGIO), this calculation reflects cost management efficiency amid a high dependence on external vendors. Outsourced production turns this metric into an indicator of operational resilience. Analyze quarterly earnings per share (EPS) growth to assess long-term potential.

Competitors of Agios Pharmaceuticals (AGIO)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months rezolutebio.com (RZLT)|Year-over-year net earnings per share growth for the last 12 months lexpharma.com LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS